Literature DB >> 20864906

Active tissue factor and activated factor XI in circulating blood of patients with systolic heart failure due to ischemic cardiomyopathy.

Michał Zabczyk1, Saulius Butenas, Ilona Palka, Jadwiga Nessler, Anetta Undas.   

Abstract

INTRODUCTION: Elevated clotting factors and thrombin generation have been reported to occur in patients with heart failure (HF). Circulating activated factor XI (FXIa) and active tissue factor (TF) can be detected in acute coronary syndromes and stable angina.
OBJECTIVES: We investigated circulating FXIa and active TF and their associations in patients with systolic HF due to ischemic cardiomyopathy. PATIENTS AND METHODS: In an observational study, we assessed 53 consecutive patients, aged below 75 years, with stable HF associated with documented coronary artery disease (CAD). Atrial fibrillation, recent thromboembolic events, and current anticoagulant therapy were the exclusion criteria. Plasma TF and FXIa activity was determined in clotting assays by measuring the response to inhibitory monoclonal antibodies.
RESULTS: Coagulant TF activity was detected in 20 patients (37.7%), and FXIa in 22 patients (41.5%). Patients with detectable TF activity and/or FXIa were younger, had a history of myocardial infarction more frequently, significantly higher F1+2 prothrombin fragments, larger left atrium (LA) and right ventricular diastolic diameter, and higher right ventricular systolic pressure than the remaining subjects (P ≤ 0.01 for all). Circulating FXIa was positively correlated with F1+2 levels (r = 0.69; P < 0.001).
CONCLUSIONS: Circulating active TF and FXIa occurred in about 40% of patients with systolic HF due to ischemic cardiomyopathy. The presence of these factors was associated with enhanced thrombin formation. Associations between both factors and LA diameter and right ventricular parameters might suggest that TF and FXIa predispose to thromboembolic complications of HF.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20864906      PMCID: PMC3168988     

Source DB:  PubMed          Journal:  Pol Arch Med Wewn


  22 in total

1.  The endogenous thrombin potential and high levels of coagulation factor VIII, factor IX and factor XI.

Authors:  Annelie Siegemund; Sirak Petros; Thomas Siegemund; Ute Scholz; Hans-Jürgen Seyfarth; Lothar Engelmann
Journal:  Blood Coagul Fibrinolysis       Date:  2004-04       Impact factor: 1.276

Review 2.  Cell membrane microparticles in blood and blood products: potentially pathogenic agents and diagnostic markers.

Authors:  Jan Simak; Monique P Gelderman
Journal:  Transfus Med Rev       Date:  2006-01

3.  Elevated levels of plasma prekallikrein, high molecular weight kininogen and factor XI in coronary heart disease.

Authors:  Christoph Merlo; Walter A Wuillemin; Maurice Redondo; Miha Furlan; Irmela Sulzer; Johanna Kremer-Hovinga; Bernd R Binder; Bernhard Lämmle
Journal:  Atherosclerosis       Date:  2002-04       Impact factor: 5.162

Review 4.  The structural basis of function of the TF. VIIa complex in the cellular initiation of coagulation.

Authors:  T S Edgington; C D Dickinson; W Ruf
Journal:  Thromb Haemost       Date:  1997-07       Impact factor: 5.249

5.  Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis.

Authors:  P A Von dem Borne; L Bajzar; J C Meijers; M E Nesheim; B N Bouma
Journal:  J Clin Invest       Date:  1997-05-15       Impact factor: 14.808

6.  Left ventricular thrombus and subsequent thromboembolism in patients with severe systolic dysfunction.

Authors:  N D Sharma; P A McCullough; E F Philbin; W D Weaver
Journal:  Chest       Date:  2000-02       Impact factor: 9.410

7.  Tissue factor expression on macrophages in coronary plaques in patients with unstable angina.

Authors:  K Kaikita; H Ogawa; H Yasue; M Takeya; K Takahashi; T Saito; K Hayasaki; K Horiuchi; A Takizawa; Y Kamikubo; S Nakamura
Journal:  Arterioscler Thromb Vasc Biol       Date:  1997-10       Impact factor: 8.311

Review 8.  Pathophysiology of coronary artery disease.

Authors:  Peter Libby; Pierre Theroux
Journal:  Circulation       Date:  2005-06-28       Impact factor: 29.690

9.  Coagulation factors IX through XIII and the risk of future venous thrombosis: the Longitudinal Investigation of Thromboembolism Etiology.

Authors:  Mary Cushman; Ellen S O'Meara; Aaron R Folsom; Susan R Heckbert
Journal:  Blood       Date:  2009-07-17       Impact factor: 22.113

Review 10.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM).

Authors:  Kenneth Dickstein; Alain Cohen-Solal; Gerasimos Filippatos; John J V McMurray; Piotr Ponikowski; Philip Alexander Poole-Wilson; Anna Strömberg; Dirk J van Veldhuisen; Dan Atar; Arno W Hoes; Andre Keren; Alexandre Mebazaa; Markku Nieminen; Silvia Giuliana Priori; Karl Swedberg
Journal:  Eur Heart J       Date:  2008-09-17       Impact factor: 29.983

View more
  11 in total

1.  Active tissue factor and activated factor XI in patients with acute ischemic cerebrovascular events.

Authors:  Anetta Undas; Agnieszka Slowik; Matthew Gissel; Kenneth G Mann; Saulius Butenas
Journal:  Eur J Clin Invest       Date:  2011-06-27       Impact factor: 4.686

2.  Activated factor XI and tissue factor in chronic obstructive pulmonary disease: links with inflammation and thrombin generation.

Authors:  Milosz Jankowski; Anetta Undas; Przemyslaw Kaczmarek; Saulius Butenas
Journal:  Thromb Res       Date:  2011-01-13       Impact factor: 3.944

Review 3.  TACTIC: Trans-Agency Consortium for Trauma-Induced Coagulopathy.

Authors:  K G Mann; K Freeman
Journal:  J Thromb Haemost       Date:  2015-06       Impact factor: 5.824

4.  Circulating activated factor XI and active tissue factor as predictors of worse prognosis in patients following ischemic cerebrovascular events.

Authors:  Anetta Undas; Agnieszka Slowik; Matthew Gissel; Kenneth G Mann; Saulius Butenas
Journal:  Thromb Res       Date:  2011-08-04       Impact factor: 3.944

5.  Synergy Between Tissue Factor and Exogenous Factor XIa in Initiating Coagulation.

Authors:  Karin Leiderman; William C Chang; Mikhail Ovanesov; Aaron L Fogelson
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-10-27       Impact factor: 8.311

6.  Global assays of hemostasis in the diagnostics of hypercoagulation and evaluation of thrombosis risk.

Authors:  Elena N Lipets; Fazoil I Ataullakhanov
Journal:  Thromb J       Date:  2015-01-23

7.  Factor XIa and Thrombin Generation Are Elevated in Patients with Acute Coronary Syndrome and Predict Recurrent Cardiovascular Events.

Authors:  Rinske Loeffen; René van Oerle; Mathie P G Leers; Johannes A Kragten; Harry Crijns; Henri M H Spronk; Hugo Ten Cate
Journal:  PLoS One       Date:  2016-07-15       Impact factor: 3.240

8.  Relationship between changes in selected thrombotic and inflammatory factors, echocardiographic parameters and the incidence of venous thrombosis after pacemaker implantation based on our own observations.

Authors:  Jacek Lelakowski; Teresa Barbara Domagała; Anna Rydlewska; Rafał Januszek; Katarzyna Kotula-Horowitz; Jacek Majewski; Andrzej Ząbek; Barbara Małecka
Journal:  Arch Med Sci       Date:  2012-05-13       Impact factor: 3.318

9.  Type 2 diabetes as a modifier of fibrin clot properties in patients with coronary artery disease.

Authors:  Maciej Bochenek; Jaroslaw Zalewski; Jerzy Sadowski; Anetta Undas
Journal:  J Thromb Thrombolysis       Date:  2013-02       Impact factor: 2.300

10.  Circulating contact-pathway-activating microparticles together with factors IXa and XIa induce spontaneous clotting in plasma of hematology and cardiologic patients.

Authors:  Elena Lipets; Olga Vlasova; Evdokiya Urnova; Oleg Margolin; Anna Soloveva; Olga Ostapushchenko; John Andersen; Fazoil Ataullakhanov; Mikhail Panteleev
Journal:  PLoS One       Date:  2014-01-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.